{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T17:55:52Z","timestamp":1778349352592,"version":"3.51.4"},"reference-count":72,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,3,3]],"date-time":"2008-03-03T00:00:00Z","timestamp":1204502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Over the last few years new immunoassays have emerged that allow the measurement of free immunoglobulin light chains (FLCs) in serum to a level of 2\u20134\u2003mg\/l and provide a much greater sensitivity than older methods, such as immunofixation, which is able to detect FLCs at a minimum concentration of 100\u2013150\u2003mg\/l. The new FLC assay has enabled the detection of monoclonal protein in some patients with non\u2010secretory myeloma and amyloidosis that were previously undetectable. FLC measurements are quantitative, correlating with disease activity, and are an advance in monitoring light chain only multiple myeloma, AL amyloidosis, non\u2010secretory and oligo\u2010secretory multiple myeloma. Serum FLC concentrations also reflect the disease course in the majority of myeloma patients producing intact monoclonal immunoglobulin proteins and have been incorporated into the new response criteria. The rapid half life of \u03bb and \u03ba free light chains means that FLC assays may provide a more rapid indication of the response to treatment but their clinical utility in this setting needs further study. An abnormal FLC ratio has been shown to be a risk factor for progression of monoclonal gammopathy of undetermined significance, smouldering myeloma and solitary plasmacytoma of bone and is prognostic in multiple myeloma.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2008.07079.x","type":"journal-article","created":{"date-parts":[[2008,3,4]],"date-time":"2008-03-04T00:06:12Z","timestamp":1204589172000},"page":"413-422","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["The evolving use of serum free light chain assays in haematology"],"prefix":"10.1111","volume":"141","author":[{"given":"Guy","family":"Pratt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,27]]},"reference":[{"key":"e_1_2_17_2_1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/clinchem\/48.4.655","article-title":"Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma","volume":"48","author":"Abraham R.S.","year":"2002","journal-title":"Clinical Chemistry"},{"key":"e_1_2_17_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11133"},{"key":"e_1_2_17_4_1","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1182\/blood.V87.3.912.bloodjournal873912","article-title":"Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy","volume":"87","author":"Baldini L.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_17_5_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.1998.275.2.F246"},{"key":"e_1_2_17_6_1","doi-asserted-by":"publisher","DOI":"10.1258\/000456307782268084"},{"key":"e_1_2_17_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70125-8"},{"key":"e_1_2_17_8_1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine","volume":"47","author":"Bradwell A.R.","year":"2001","journal-title":"Clinical Chemistry"},{"key":"e_1_2_17_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12457-9"},{"key":"e_1_2_17_10_1","doi-asserted-by":"crossref","first-page":"972a","DOI":"10.1182\/blood.V106.11.3482.3482","article-title":"Rapid removal of free light chains from serum bu hemodialysis for patients with myeloma kidney","volume":"106","author":"Bradwell A.R.","year":"2005","journal-title":"Blood"},{"key":"e_1_2_17_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh749"},{"key":"e_1_2_17_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.6.1625"},{"key":"e_1_2_17_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-11-200512060-00005"},{"key":"e_1_2_17_14_1","first-page":"C145","article-title":"Incidence of antigen excess in serum free light chain assays","volume":"53","author":"Clark R.J.","year":"2007","journal-title":"Clinical Chemistry"},{"key":"e_1_2_17_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10297"},{"key":"e_1_2_17_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V64.6.1207.1207"},{"key":"e_1_2_17_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015784"},{"key":"e_1_2_17_18_1","doi-asserted-by":"publisher","DOI":"10.4065\/76.5.476"},{"key":"e_1_2_17_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2922"},{"key":"e_1_2_17_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-108357"},{"key":"e_1_2_17_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.9.2900"},{"key":"e_1_2_17_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-008953"},{"key":"e_1_2_17_23_1","first-page":"665a","article-title":"Survival from relapse and the influence of therapy","volume":"92","author":"Drayson M.T.","year":"2007","journal-title":"Haematologica"},{"key":"e_1_2_17_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.111"},{"key":"e_1_2_17_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_17_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20381"},{"key":"e_1_2_17_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05848.x"},{"key":"e_1_2_17_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-185"},{"key":"e_1_2_17_29_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2006.069104"},{"key":"e_1_2_17_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1969.tb00441.x"},{"key":"e_1_2_17_31_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006080821"},{"key":"e_1_2_17_32_1","doi-asserted-by":"crossref","first-page":"2419a","DOI":"10.1182\/blood.V108.11.2419.2419","article-title":"Serum free light chain (SFLC) elevation is associated with high \u03b22\u2010microglobulin and with a shorter time to treatment in Waldenstroms macroglobulinemia","volume":"108","author":"Itzykson R.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_17_33_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.11.5512"},{"key":"e_1_2_17_34_1","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains","volume":"48","author":"Katzmann J.A.","year":"2002","journal-title":"Clinical Chemistry"},{"key":"e_1_2_17_35_1","first-page":"74a","article-title":"Monoclonal free light chains in sera from healthy individuals: FLC MGUS","volume":"49","author":"Katzmann J.A.","year":"2003","journal-title":"Clinical Chemistry"},{"key":"e_1_2_17_36_1","doi-asserted-by":"crossref","first-page":"757a","DOI":"10.1182\/blood.V104.11.757.757","article-title":"Performance of free light chain assays in clinical practice","volume":"104","author":"Katzmann J.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_17_37_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2004.046870"},{"key":"e_1_2_17_38_1","doi-asserted-by":"publisher","DOI":"10.4065\/81.12.1575"},{"key":"e_1_2_17_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb00190.x"},{"key":"e_1_2_17_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.159"},{"key":"e_1_2_17_41_1","doi-asserted-by":"crossref","first-page":"3514a","DOI":"10.1182\/blood.V108.11.3514.3514","article-title":"High incidence of IgH translocations in monoclonal gammopathies with abnormal free light chain levels","volume":"108","author":"Kumar S.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_17_42_1","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle R.A.","year":"1995","journal-title":"Seminars in Hematology"},{"key":"e_1_2_17_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06235.x"},{"key":"e_1_2_17_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa01133202"},{"key":"e_1_2_17_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06561.x"},{"key":"e_1_2_17_46_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04433.x"},{"key":"e_1_2_17_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2006.11.001"},{"key":"e_1_2_17_48_1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.V60.4.851.851","article-title":"Myeloma protein kinetics following chemotherapy","volume":"60","author":"McLaughlin P.","year":"1982","journal-title":"Blood"},{"key":"e_1_2_17_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05045.x"},{"key":"e_1_2_17_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(67)90036-8"},{"key":"e_1_2_17_51_1","doi-asserted-by":"crossref","first-page":"2420a","DOI":"10.1182\/blood.V108.11.2420.2420","article-title":"Serum free light chain in Waldenstom macroglobulinemia","volume":"108","author":"Moreau A.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_17_52_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10568"},{"key":"e_1_2_17_53_1","first-page":"5197a","article-title":"Free light chain measurement in serum compared with immunofixation of urine in patients with multiple myeloma","volume":"102","author":"Nowrousian M.R.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_17_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4385"},{"key":"e_1_2_17_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1996.tb00314.x"},{"key":"e_1_2_17_56_1","doi-asserted-by":"publisher","DOI":"10.1159\/000206123"},{"key":"e_1_2_17_57_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500254216"},{"key":"e_1_2_17_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1038"},{"key":"e_1_2_17_59_1","first-page":"79a","article-title":"Serum free light chain assays for determining complete remission in mulitple myeloma patients","volume":"50","author":"Reid S.D.","year":"2004","journal-title":"Clinical Chemistry"},{"key":"e_1_2_17_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-067728"},{"key":"e_1_2_17_61_1","first-page":"1019a","article-title":"Free light chain analysis in patients receiving bortezomib","volume":"92","author":"Robson E.","year":"2007","journal-title":"Haematologica"},{"key":"e_1_2_17_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705106"},{"key":"e_1_2_17_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04884.x"},{"key":"e_1_2_17_64_1","doi-asserted-by":"publisher","DOI":"10.1258\/000456307782268183"},{"key":"e_1_2_17_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-060368"},{"key":"e_1_2_17_66_1","first-page":"5195a","article-title":"Serum free light chain assessment in myeloma patients who are in complete remission (CR) by immunofixation predicts early relapse","volume":"102","author":"Sirohi B.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_17_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05867.x"},{"key":"e_1_2_17_68_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI104884"},{"key":"e_1_2_17_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05338.x"},{"key":"e_1_2_17_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2006.07.011"},{"issue":"1","key":"e_1_2_17_71_1","first-page":"141","article-title":"Free light chains (FLC) of immunoglobulins as parameter resembling disease activity in autoimmune rheumatic diseases","volume":"63","author":"Urban S.","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"key":"e_1_2_17_72_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107023"},{"key":"e_1_2_17_73_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.126.2.207"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2008.07079.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2008.07079.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:44:47Z","timestamp":1697424287000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2008.07079.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,27]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1111\/j.1365-2141.2008.07079.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07079.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,27]]},"assertion":[{"value":"2008-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}